CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
about
Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic TargetingInterplay between Cellular and Molecular Inflammatory Mediators in Lung CancerAdvances in Cancer Immunotherapy in Solid TumorsStructural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapyVedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis.Cancer Immunoprevention and Public Health.Intratumoral FoxP3+Helios+ Regulatory T Cells Upregulating Immunosuppressive Molecules Are Expanded in Human Colorectal Cancer.Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment.Flare-Up of Rheumatoid Arthritis by Anti-CTLA-4 Antibody but Not by Anti-PD1 Therapy in a Patient with Metastatic Melanoma.Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitisNovel systemic therapy against malignant pleural mesothelioma.Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab.Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer.Immune based therapy for melanomaActivation and Recruitment of Regulatory T Cells via Chemokine Receptor Activation in Trichinella spiralis-Infected Mice.Molecular Imaging of Immunotherapy Targets in Cancer.Excerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, Norway.Culture supernatant of adipose stem cells can ameliorate allergic airway inflammation via recruitment of CD4+CD25+Foxp3 T cellsThe Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start.Immunotherapy of Prostate Cancer: Facts and Hopes.A perspective on the impact of radiation therapy on the immune rheostat.Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.Advancing Cancer Therapy with Present and Emerging Immuno-Oncology ApproachesEbola Virus Disease in Humans: Pathophysiology and Immunity.Immunotherapy for gastric cancers: emerging role and future perspectives.Diagnostic performance of CTLA-4, carcinoembryonic antigen and CYFRA 21-1 for malignant pleural effusion.Immune checkpoints and their inhibition in cancer and infectious diseases.Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer.Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas.Anti-CTLA-4 therapy for malignant mesothelioma.Aptamers for CD Antigens: From Cell Profiling to Activity Modulation.CD8 T-cell regulation by T regulatory cells and the programmed cell death protein 1 pathway.Regional immunotherapy for liver and peritoneal metastases.Intimate cross-talk between cancer cells and the tumor microenvironment of B-cell lymphomas: The key role of exosomes.Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer.Current status and future prospects for human papillomavirus vaccines.Harnessing CXCR4 antagonists in stem cell mobilization, HIV infection, ischemic diseases, and oncology.Increased infiltration and tolerised antigen-specific CD8+ TEM cells in tumor but not peripheral blood have no impact on survival of HCMV+ glioblastoma patients.Whole genome gene expression changes and hematological effects of rikkunshito in patients with advanced non-small cell lung cancer receiving first line chemotherapy.
P2860
Q26742012-DD86EA5F-347A-4930-A72D-64D58C52CB53Q26768652-BCB4261C-F611-4003-B8F7-0B4A3773F678Q28080113-7493146A-542C-4E34-8AAB-A90C7DF60964Q28314934-7032D257-75B8-4653-A974-73E9B4581E4EQ33607108-8B33C9AC-1397-4DB5-94B5-CC6A351C4FFEQ33646584-8B232F25-2A59-4D24-9284-6B70CF1B4B6FQ33729278-BA07ED75-6071-4FFB-8A20-D7EB45A4A5C5Q33779401-D83CAD36-985F-4417-B317-5B9D003054E2Q33782050-8D10D9F1-A42D-47E0-B89D-C6E655752E89Q33813378-D709725E-6E57-4BC4-AF79-FF1F46212DCAQ33890499-4CBD0F8A-7EF6-409A-8EE0-36E44AAC4D21Q33912075-9742919B-3B15-444E-9930-B9E24EF8CF11Q34545316-CF24B3E1-976D-4556-8AD3-05CD92B1DBF0Q36876757-3498F434-43D6-429C-817F-C024DA7BC212Q36911858-D9862980-F290-4984-A698-880D41C4B5C0Q37309882-88629277-1E5A-4D45-A79A-1AEBE4238218Q37349280-DFF039F5-19F0-496D-8606-0260AB910F94Q37602396-9826A2C2-3D27-439B-B5D4-3B3F87840988Q38401891-EAC860A8-97A4-4035-9C1A-9F08447327F4Q38638500-1FD14324-6EC8-4955-B317-1F35A9C6B03FQ38664882-373D6226-76A4-4874-8819-BC901DB495EAQ38679488-B04DCCE4-308A-4687-886C-0388FCF74648Q38685278-106A4220-A318-4C2B-8EF1-0B50B9178E2EQ38689153-05D02A38-EB4E-481B-9E6D-4A5C012BFED1Q38707770-49B00C57-9974-4645-B717-44026779E977Q38738652-7572BA78-9259-494E-81FA-D93D993E6392Q38785402-9D2C5A8A-654B-41BD-A06F-4AA863EB3952Q38845026-508BBE70-150A-49E2-89B2-5D3D8E8D20F8Q38870763-23E682A6-B185-4095-AE3C-241F9B4A667EQ38887303-88FE02FE-BF2E-4FBB-9DA2-2B6F2F0F2224Q39148274-DF37A8C7-6865-4CC0-B126-39BE3EDF051EQ39191316-3EB72572-68EE-4D7D-A663-497E6CAF5E70Q39218899-FFEF7F0D-BC24-4497-A999-3EEFD91D69A9Q39329364-D2FD30BC-4554-429A-BF6A-5375EA78422EQ39376074-DAD1C0C5-50F9-44A2-A44E-308408F5C87FQ39402079-10C83BC5-0B2A-4331-96AD-F360156D8548Q40056541-EF00EEFE-8D44-4D30-AFAF-8BC2695BB744Q40109819-D33B68CF-05A2-40C8-851F-5FE9A2FBBBC6Q41338250-F1D78A3E-ED8A-4DA0-A92C-86A64B80B7EDQ41672333-2FB26A33-11B8-416A-BB9D-C1E10F670354
P2860
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
description
2016 nî lūn-bûn
@nan
2016 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
@ast
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
@en
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
@nl
type
label
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
@ast
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
@en
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
@nl
prefLabel
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
@ast
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
@en
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
@nl
P2860
P921
P3181
P1476
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
@en
P2093
Anupam Desai
Elizabeth I Buchbinder
P2860
P304
P3181
P356
10.1097/COC.0000000000000239
P407
P5008
P577
2016-02-01T00:00:00Z